Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crataegus gracilior petroleum ether extract is a research-stage botanical extract derived from the stems and leaves of Mexican hawthorn (*Crataegus gracilior* J. B. Phipps). Unlike other hawthorn species whose antitumor activity resides in polar extracts, the petroleum ether fraction of *C. gracilior* uniquely exhibits cytotoxic properties against breast cancer cells, inducing cell death via apoptosis. The active compounds identified in this extract are β-sitosterol and tocopherol, whose combined activity is believed to drive its cytotoxic and pro-apoptotic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Crataegus gracilior petroleum ether extract.